Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
BIO CEO & Investor Conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...
Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for ...
Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today ...
First patient dosed in Phase Ib Pompe disease trial
The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe ...
Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...
The EMBO Journal20 天
Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto ...
By depleting PTG, an activator of the glycogen chain-elongating enzyme glycogen synthase (GYS1), in laforin- and malin-deficient LD mice, we show that abnormal glycogen chain lengths and not ...
Pharmaceutical Technology29 天
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European ...